BTG PLC (BTG.L) Quote| Reuters.com
Edition:
United States

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

651.00GBp
24 Jun 2016
Change (% chg)

-5.00p (-0.76%)
Prev Close
656.00p
Open
608.50p
Day's High
662.50p
Day's Low
608.50p
Volume
1,200,473
Avg. Vol
620,261
52-wk High
699.50p
52-wk Low
504.00p

BTG.L

Chart for BTG.L

About

BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company's Interventional Medicine segment offers a portfolio of... (more)

Overall

Beta: 0.38
Market Cap(Mil.): £2,493.30
Shares Outstanding(Mil.): 383.00
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 41.77 32.69 34.11
EPS (TTM): 0.16 -- --
ROI: 6.19 15.00 14.23
ROE: 7.53 16.08 15.46

UPDATE 1-BTG Group FY profit doubles, sees 8-15 pct rev growth

(Adds forecast, analyst comment, share movement) May 17 British healthcare group BTG Plc said its full-year pretax profit doubled from a year earlier as sales of its interventional therapies picked up, and forecast an 8-15 percent revenue growth for the next year. BTG shares rose as much as 2.4 percent to 600.50 pence on Tuesday morning. BTG said it expected revenue to be in the range 485 million pounds to 515 million pounds ($703.6 million-$746.7 million) for the fin

May 17 2016

BTG Group FY pretax profit doubles

May 17 British healthcare group BTG said its full-year pretax profit doubled from a year earlier on strong revenue growth.

May 17 2016

BRIEF-Galil medical announces agreement to acquisition by Btg Plc

* Galil Medical announces agreement to acquisition by Btg Plc Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 06 2016

Britain's BTG buys tumor freezing company Galil Medical

LONDON British healthcare group BTG said is had agreed to buy Galil Medical, a U.S. company that makes cryoablation products to treat Kidney and other cancers by freezing and destroying tumors, for an initial cash payment of $84.5 million.

May 06 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Sadif Analytics Prime
$10.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.